Novartis AG (NVS) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Novartis AG (NVS) surged +3.22% to $161.10 as options desks priced 57% call premium vs. 43% put protection around the $158 max-pain magnet. Solid 41% profit margin (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.
Oil has quietly moved back to the center of the story, with Brent forecasts being revised higher and geopolitical risk now baked into every barrel. That ripple effect touches funding costs, inflation expectations, and wh
France just received a reminder that its finances are under scrutiny, with Fitch flagging weaker growth, a stretched budget and rising political risk. When a major rating agency questions a country’s trajectory, domestic
Novartis is rated Hold, with a 12-month price target of $141.81, implying a 12.0% downside from the current share price. Read more on NVS stock here.
Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Players: Pfizer, Novartis, Bayer, Astellas and Sarepta. Profile: next-gen AAV delivery, including engineered capsids, targeting, safety and scalable manufacturing.Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Next-Generatio
Boost ROI via targeted siRNA delivery, personalized therapies, pipeline-expanding acquisitions, and focus on renal, rare, neurological and oncology indications.Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Gene Silencing Th
AstraZeneca aims to free up funds to reinvest into its pipeline and meet its goal of $80 billion in annual revenue by 2030.
Alnylam's shares fall 25% despite Q3 beat as slower Amvuttra patient starts and demand concerns weigh on investor sentiment.
Deutsche Bank analyst Emmanuel Papadakis downgrades Novartis (NYSE:NVS) from Hold to Sell.
Here is how Avantor, Inc. (AVTR) and Novartis (NVS) have performed compared to their sector so far this year.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +15.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NVS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NVS. Explore sector supply chains on /butterfly.
Why NVS Stock surged +3.22% Today — RQD Quant Desk Flash. Solid 41% profit margin (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.